Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Temelimab SAD Study in Healthy Volunteers
NCT03574428Phase 1Completed
- Sponsor
- GeNeuro
- Start
- May 2018
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of temelimab in multiple sclerosis (MS) (4 cohorts), sponsored by GeNeuro. Primary endpoint: Safety and tolerability of single ascending doses of GNbAC1 at 57 days. Started May 2018; status: completed.
02
Drugs
temelimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03574428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574428.